Scoop: Just months after Sanofi AI deal, Atomwise laid off 30% of staffers amid 'strategic shift'
Atomwise, a well-connected player in the burgeoning space of artificial intelligence-powered drug discovery, cut its headcount by 30% in December, Endpoints News has learned.
CEO and co-founder Abraham Heifets confirmed the layoffs, which resulted in around 30 people departing the company.
“We had to make some very hard decisions and part ways with some fantastic colleagues,” he wrote in an email.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.